BC Extra | Sep 5, 2019
Financial News

Sept. 5 Financial Quick Takes: Zealand raises cash as it readies NDA; plus Bellus, Aerie, LNC, Veralox and Sigrid

Ahead of NDA submission, Zealand raising cash  Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) is raising DKK559.6 million ($82.4 million) via a private placement and directed share issue to existing investor Van Herk Investments. Zealand will sell...
BC Extra | Sep 4, 2019
Financial News

Sept. 4 Financial Quick Takes: BrightGene looks to STAR; plus IPO updates from Immunotech, 10x Genomics, SpringWorks, IGM, Satsuma and more

BrightGene advances toward STAR market   The Shanghai Stock Exchange approved an application from BrightGene Bio-Medical Technology Co. Ltd. (Suzhou, China) to raise RMB360 million ($50.3 million) in a listing on its STAR market. If...
BC Extra | Jun 20, 2019
Company News

Beyond Keytruda: Merck details plans for future growth

Merck is looking beyond its blockbuster cancer drug Keytruda pembrolizumab to late-stage programs in infectious disease, vaccines and chronic indications to help the pharma weather any revenue shortcomings when its diabetes drug Januvia sitagliptin comes...
BC Innovations | May 28, 2019
Distillery Therapeutics

Inhibition of VEGF-A, P2RX7 or the combination of FLT1 and VEGFR-2 to treat tuberculosis

DISEASE CATEGORY: Infectious disease INDICATION: Tuberculosis Mouse studies suggest inhibiting VEGF-A, P2RX7 or the combination of FLT1 and VEGFR-2 could help treat tuberculosis (TB). In a mouse model of TB, expression of mutant VEGF-A with...
BC Innovations | Apr 17, 2019
Emerging Company Profile

Nocion: Targeting pain neurons and nothing else

With a $27 million series A co-led by Canaan and F-Prime Capital announced Wednesday, Nocion thinks it could replace opioids in a range of tissue-localized indications, starting with cough. The company is aiming to minimize...
BC Innovations | Feb 5, 2019
Distillery Therapeutics

Neurology

INDICATION: Autism Mouse studies suggest inhibiting P2RX7 could help treat autism. In a mouse model of autism, systemic knockout of P2RX7 or a tool compound P2RX7 inhibitor tool decreased social deficits, sensorimotor coordination impairment and...
BC Innovations | Sep 26, 2018
Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs A SNP on P2RX7 could help predict outcomes in heart transplant patients. In 102 heart transplant patients, P2RX7 genotyping identified an association between a SNP on P2RX7 (rs3751143) and the risk of rapidly...
BC Innovations | Aug 16, 2018
Distillery Therapeutics

Neurology

INDICATION: Pain Mouse and rat studies suggest inhibiting PANX1 or its activator P2RX7 in spinal microglia, or an antibody-drug conjugate (ADC) targeting the microglia, could help treat joint pain. In spinal cord samples from a...
BC Innovations | Jan 23, 2018
Distillery Therapeutics

Transplant

INDICATION: Graft rejection Patient sample and mouse studies suggest inhibiting P2RX7 could help treat transplant rejection. In blood samples from liver transplant patients, monocyte levels of P2RX7 were higher in patients who rejected their transplants...
BC Week In Review | Dec 15, 2017
Financial News

Bellus Health raises C$20M in follow-on

On Dec. 12, Bellus Health Inc. (TSX:BLU) raised C$20 million ($15.6 million) through the sale of 52.6 million shares at C$0.38 in a follow-on. The price values the company at C$45.4 million ($35.4 million). Bloom...
Items per page:
1 - 10 of 53